Phase I trial of omecamtiv mecarbil in healthy volunteers of Japanese and non-Japanese ethnicity
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2014
Price : $35 *
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Angina pectoris; Cardiomyopathies; Heart failure
- Focus Pharmacokinetics
- Sponsors Amgen
- 27 Oct 2014 Top-line results published in a Cytokinetics media release.
- 27 Oct 2014 Status changed from recruiting to completed, as reported by a Cytokinetics media release.
- 30 Jul 2014 Status changed from planning to recruiting according to a Cytokinetics media release.